In a recent research study conducted by Sanofi US (Sanofi, digital therapeutics company DarioHealth’s (Dario) digital health solution has demonstrated significant reductions in healthcare resource utilisation.

Dario offers an integrated multi-chronic condition platform to address the most common chronic conditions. The platform enables improved clinical outcomes to reduce the cost of care associated with chronic diseases.

The Dario digital diabetes solution comprises a connected smart blood glucose meter and a mobile application, providing a personalised approach to users to manage their health. The glucose meter is approved by the US Food and Drug Administration.

The results of a retrospective cohort study evaluating real-world data of users of the Dario digital health solution compared with non-users were presented at the ongoing ISPOR 2023 global conference for health economics and outcomes research in Boston, US.

The results showed a 9.3% reduction in all-cause healthcare resource utilisation, including a 23.5% reduction in hospitalisations, in users of Dario’s digital diabetes solution, at the end of 12 months.

The impact of the digital solution across total healthcare utilisation proves that a following whole-health approach for the management of chronic conditions such as diabetes can potentially lead to reduced utilisation rates and subsequent cost savings.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

This is the first study completed by Sanofi under its $30m, multi-year strategic agreement with Dario, which was signed in March last year.

Under the agreement, the companies will work towards accelerating the commercialisation of Dario’s full suite of digital therapeutics. The agreement also focuses on the development of digital health solutions on the Dario platform.

Dario chief medical officer Omar Manejwala said: “We are incredibly proud of this new research demonstrating Dario’s ability to potentially reduce healthcare utilisation through a holistic, user-centric digital health solution.

“These results are important not only to our clients and partners who are looking for solutions to help reduce the cost of care but also to the market as we push for more accountability in digital health research.”

The companies will continue to evaluate the impact of the Dario platform on clinical, resource utilisation and financial outcomes.